| Date | Title | Description |
| 10.07.2024 | Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions | CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and promotions. Today's personnel announcement acco... |
| 19.01.2023 | EQRx promised to deliver cutting-edge drugs at half the cost of rivals. A cofounder shares why the once buzzy biotech is walking away from that mission | EQRx cofounder and executive chairman Alexis Borisy EQRx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
After years of touting the idea of radically lower drug prices, EQRx has walked aw... |
| 12.01.2023 | Alphabet's Verily announces layoffs amid strategic restructuring | Photo: filadendron/Getty Images |
| 12.09.2022 | Alphabet's Verily raises $1B to expand precision health business | Photo: JL Images/Getty Images |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself, others block its a... |
| 18.01.2022 | EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer | Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent... |
| 16.11.2021 | EQRx Launches “Remaking Medicine: On The Record” Investor Video Series | EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today launched a multi-part corporate video series entitled “Remaking Medicine: On The Record.”... |
| 26.10.2021 | Why serial biotech entrepreneur Alexis Borisy wants to stop the 'great big party' on drug pricing and take on his own industry | The EQRx cofounder and chairman Alexis Borisy. EQRx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Alexis Borisy has helped launch more than a dozen biotechs, but EQRx might b... |
| 23.08.2021 | A new kind of biotech is aiming to undercut Big Pharma with cheaper drugs. But skeptics question whether EQRx is just hype. | A scientist works in a lab at the pharmaceutical company Pfizer. Pat Greenhouse/The Boston Globe via Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
EQRx is raisin... |
| 10.08.2021 | UPDATED: Virtually unknown mRNA upstart rides SPAC to Nasdaq with a $1.5B valuation as RA-backed neuro player prices IPO | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Just a few days after EQRx announced its intent to merge with Eli Casdin’s third blank check company, anoth... |
| 09.08.2021 | AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next? | In one of the more unlikely bidding wars in recent biopharma memory, a British tobacco giant and a US private equity firm are competing to purchase a UK drugmaker whose last experimental drug failed three years ago.
Overnight Monday both Ph... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | Moderna’s little business deal with Autolus earlier this week looks like a predinner snack ahead of the main course to come.
During his Q2 call with analysts on Thursday, Moderna CEO Stéphane Bancel got more than a few eyebrows to raise wit... |
| 06.08.2021 | Vertex taps longtime commercial lead to fill two-year COO vacancy; Nancy Thornberry set for different role at Kallyope with an old friend from Merck waiting in the wings | For the first time in two years, Vertex has a COO.
Stuart Arbuckle
The cystic fibrosis drugmaker announced Wednesday that Stuart Arbuckle, who has led the company’s commercial efforts since 2012, has been appointed to r... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | EQRx, a would-be drug pricing disruptor that has emerged as an investor darling, has everything but an approval to show in its fight against financial toxicity in biopharma. With the homestretch closing in, the team is now ready for its clo... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The biotech industry was set to end this week with another two major public debuts. The first company, Tillman Gerngross’ antib... |
| 06.08.2021 | Sanofi wins approval for Lumizyme successor, although uptake remains a mystery | It’s not yet clear how many patients will actually take it, but for the first time in 15 years, there is a new treatment available for the rare and deadly genetic condition Pompe disease.
The FDA approved avalglucosidase al... |
| 06.08.2021 | Bitcoin mining is having a moment right now, but will it last? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Hurl whatever skepticism you want at Bitcoin, but the process of mining the cryptocurrency is, we... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | Rack up another delay for Novavax $NVAX on the crucial EUA front.
The biotech’s Q2 review dropped after the market close on Thursday, and with it came the news that their request for an emergency use approval of their Covid-19 vaccine at th... |
| 06.08.2021 | FDA orders clinical hold on Aprea's p53 reactivator as struggling biotech pledges to address safety concerns | Little Aprea Therapeutics just tripped yet again on its rocky path to develop a drug that can reactivate the mutant tumor suppressor protein p53.
The Boston-based biotech said the FDA has placed a partial clinical hold on i... |
| 06.08.2021 | Chinese startup with Merck vet at the helm acquires rights to Oyster Point's eye disease nasal spray | With the Chinese drug market starting to bear fruit, Western drugmakers have looked to wiggle their way in, often leaning on local partners to do the grunt work on the ground. With so many Chinese companies playing the willi... |
| 06.08.2021 | Senate Dems call to add Medicare drug price negotiations to reconciliation bill; Certara signs $310M buyout of software company | Don’t forget to include drug pricing reforms in the upcoming $3.5 trillion reconciliation bill, Sens. Amy Klobuchar (D-MN), Dianne Feinstein (D-CA) and 10 of their colleagues urged Senate leaders Chuck Schumer, Bernie Sand... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | Normally, new generic drug competition can enter the market for one or some of the approved indications of its brand-name counterpart’s label. That new generic drug’s label, known as a “skinny” label because it doesn’t include all of the re... |
| 06.08.2021 | Court decision pushes FDA to make historical shift and regulate borderline drug/device products as devices | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| 28.05.2021 | CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application | Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or ... |
| 12.01.2021 | One year after founding, startup EQRx raises $500M to advance goal of cheaper cancer drugs | Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yu... |
| 12.01.2021 | Affordable drug developer EQRx lands $500M | EQRx has raised $500 million in a Series B, bringing the company's total fundraising to about $750 million. All of the startup's Series A investors, which include GV, Andreessen Horowitz and Arch Venture Partners, contributed to the new rou... |
| 12.01.2021 | Daily funding roundup - January 11th, 2021 | Aulos Bioscience has raised $40M; Komodo Health landed $44M; EQRx secured $500M
Hello Ralphie: Hello Ralphie is a New York-based veterinary telemedicine company. Hello Ralphie raised $1 million in seed funding from HearstLab and WPMC Fund. ... |
| 11.01.2021 | EQRx Closes $500 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. Since launching a year ago, EQRx has r... |
| 11.01.2021 | EQRx scores $500M to drive its disruptive drug pricing model and late-stage oncology hopefuls to market | Nearly a year into its mission of rewriting the rules of drug pricing, EQRx has made a few key late-stage pickups to speed up its march to market. With the ball rolling faster than expected, investors are jumping on board in drov... |
| 11.01.2021 | EQRx : Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing | EQRx, a company committed to developing and delivering important new medicines at lower prices, today announced that it has raised $500 million in Series B financing. Since launching a year ago, EQRx has raised approximately $750 million to... |
| 18.01.2020 | Pharma startup EQRx launches with a $200 million Series A to make patent-protected drugs with lower prices | Happy weekend, folks. It’s been really cold here with freezing rain. Anyway, it’s not clear why we missed the story of EQRx, a biotech startup that launched this week with $200 million in series A funding to develop patent-protected drugs t... |
| 17.01.2020 | EQRx Raises $200 Million To Make Medicines More Affordable | EQRx recently announced it is launching to create novel patent-protected medicines for affordable prices. And the company also raised $200 million.
EQRx recently announced it is launching to create novel patent-protected medicines for price... |
| 14.01.2020 | EQRx Launches with $200M Series A Financing |
CAMBRIDGE, MA, EQRx is launching with $200M in Series A financing led by GV, ARCH Venture Partners, and Andreessen Horowitz.
>> Click here for more funding data on EQRx
>> To export EQRx funding data to PDF and Excel, click ... |
| 13.01.2020 | EQRx Launches With $200M Series A For Cheaper Drugs | 27 Shares Email Facebook Twitter LinkedIn
We’ve all read the headlines of people with diseases or illnesses that end up not surviving due to the inability to pay for the necessary medicines. While these stories are heartbreaking, they proba... |
| 13.01.2020 | EQRx Launches With $200M Series A For Cheaper Drugs | 29 Shares Email Facebook Twitter LinkedIn
We’ve all read the headlines of people with diseases or illnesses that end up not surviving due to the inability to pay for the necessary medicines. While these stories are heartbreaking, they proba... |
| 12.01.2020 | JPM: JetBlue, but for biopharma: Borisy's EQRx nabs $200M, takes aim at drug prices | SAN FRANCISCO—It's not news: Over time, biopharma companies have raised the price of new medicines ever higher—simply because they can, says veteran biotech investor Alexis Borisy. Now, he’s throwing a wrench in the system with a new kind o... |
| 12.01.2020 | With $200M Series A, EQRx aims to tackle high drug prices | The company aims to provide what it calls a market-based solution for the rising cost of drugs by changing the process of creating medicines from discovery all the way through to patient delivery in order to make the process cheaper. It wil... |
| - | With $200M Series A, EQRx aims to tackle high drug prices | In a story summarizing biopharma executives’ forecasts for 2020 last weekend, one said that while it may take a political solution to address the issue of high out-of-pocket costs for patients, it would be up to drugmakers themselves to bri... |
| - | Investors aren't buying EQRx's pitch for 'radically lower' drug prices. The CEO of the $3 billion startup tells us why she's doubling down despite a stock drop. | EQRx CEO Melanie Nallicheri. EQRx This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
EQRx is pursuing a new way to sell lower-priced drugs with no TV ads and no sales reps.
Since ... |
| - | One year after founding, startup EQRx raises $500M to advance goal of cheaper cancer drugs | A high-powered startup has raised $500 million toward its goal of making drugs for cancer and other chronic diseases more affordable and unveiled some of its most promising candidates.
The company, Cambridge, Massachusetts-based EQRx, was c... |
